Company Profile
Lisata Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Lisata Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lisata Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Lisata Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Lisata Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
LSTA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Lisata’s catalysts are certepetide and the pancreatic-cancer / solid-tumor development path, where the next update matters a lot. The company still needs stronger clinical proof.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Source: Lisata Therapeutics
- 03
Lisata Therapeutics to Present at LD Micro Main Event XIX
Source: Lisata Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.